Evaluation of Effectiveness of Combining High Protein Intake With Early Physical Exercise During Critical Illness
Evaluation of Effectiveness of Combining High Protein Intake With Early Physical Exercise During Critical Illness to Maintain Muscle Mass in Intensive Care Unite Patient.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Tanta, Egypt, 31527
- Tanta University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients in age group 18-60 years
- Expected Intensive Care Unit stay >4days after enrolment (to permit adequate exposure to the proposed intervention)
- Previously healthy, Well-nourished, subjects (nutric score=0)
Exclusion Criteria:
- Renal, liver or heart disease or chronic obstructive pulmonary disease
- Previous immune abnormalities (including treatment with corticosteroids)
- Past history of nutritional problems, chronic use of drugs (as drugs inducing myopathies) or orthopedic problems (such as skeletal fractures or immobilization) in the previous 2 years
- Neuromuscular diseases and patients with amputated lower limbs
- Past or recent history of cancer
- Long term critically ill patients shifted from other hospitals
- Pregnant patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard care
Patients will receive usual care in Intensive Care Unit (prescription of a standard nutrition formula (at approximately 20 -25 kcal/ kg/day and protein intake 1.2 g/kg/day) once patients are hemodynamically stable.
|
Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
|
|
Active Comparator: Protein and exercise group
patients will receive the amino acid intervention that is provided in addition to 'usual care' enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization).
The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).
The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
|
Amino acid enteral and/or parenteral nutrition either enteral or parenteral to target a total protein delivery of 2.0g/kg/day.
The physical exercise intervention will be delivered by trained nursing staff, and started as close to the time of randomization as feasible (within 24hours of randomization).
The intervention group will receive exercise sessions, for up to 20 min duration (as tolerated by patient).The implementation of physical exercise intervention will be protocolized to provide passive exercise early before weaning and shift to active exercise after weaning and also graduated resistance during each session and between daily sessions.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quantitative changes (cross-section diameter) of rectus femoris muscle
Time Frame: Up to 30 days of Surgical Intensive Care Unit stay.
|
Rectus femoris cross-sectional area (RFCSA) will be measured by B-mode ultrasonography using a 3 to 12 MHz transducer array.
Patient will be positioned supine in 30° upper body elevation, with legs extended and muscles relaxed.
The point that represented 60% of the distance from the anterior superior iliac spine to the superior border of the patella will be identified.
The ultrasound probe will be positioned perpendicularly along the superior aspect of the right thigh and transverse images of the rectus femoris will be obtained.
A copious amount of gel will be applied to minimize tissue compression.
The inner echogenic line of the Rectus Femoris will be traced manually on a frozen image and RFCSA will be calculated by planimetric technique.
|
Up to 30 days of Surgical Intensive Care Unit stay.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional capacity.
Time Frame: Up to 30 days of Surgical Intensive Care Unit stay.
|
Ultrasound evaluation of the rectus femoris muscle
|
Up to 30 days of Surgical Intensive Care Unit stay.
|
|
Duration of mechanical ventilation.
Time Frame: Up to 30 days of Surgical Intensive Care Unit stay.
|
Duration of mechanical ventilation.
|
Up to 30 days of Surgical Intensive Care Unit stay.
|
|
Length of Surgical Intensive Care Unit stay.
Time Frame: Up to 30 days
|
Length of Surgical Intensive Care Unit stay.
|
Up to 30 days
|
|
Mortality rate in Surgical Intensive Care Unit
Time Frame: Up to 30 days
|
Rate of death in Surgical Intensive Care Unit
|
Up to 30 days
|
|
Rate of hospital acquired infection.
Time Frame: Up to 30 days
|
Rate of hospital acquired infection.
|
Up to 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 34750/6/21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.